THE DEAL, AT A GLANCE
From the announcementNovaGo
01What it doesNovaGo develops anti-Nogo-A biologics for central nervous system diseases.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by Neurimmune, Pureos, existing, new investorsFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedNovaGo raised $30M Series B, announced 2026-09-02From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersNovaGo's $30M Series B is a median round-size signal in a crowded FinTech funding tape, with Neurimmune leading capital into a company developing anti-Nogo-A biologics…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
NovaGo · Financing Record
Explore source-linked visual explanations for NovaGo. Unsupported claims are withheld while source review continues.
Record 11771 · Recorded date: 2026-09-02
Explore company records →